Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Semaphorin 3F antisense RNA 1 (SEMA3F-AS1)
- Target
- SEMA3F-AS1
- Molecular classification
- Long noncoding RNA (lncRNA), Antisense RNA
01
Overview
Semaphorin 3F antisense RNA 1 (SEMA3F-AS1) is a long noncoding antisense RNA transcribed opposite the SEMA3F gene. Its primary biological role is the regulation of SEMA3F expression, influencing processes such as cell proliferation, migration, invasion, and potentially apoptosis and angiogenesis. SEMA3F-AS1 can act through chromatin remodeling and epigenetic mechanisms, such as histone modification, to modulate expression of tumor suppressors or oncogenes. Dysfunction or aberrant expression of SEMA3F-AS1 is implicated in several cancers, with altered levels serving as diagnostic or prognostic biomarkers. While not a receptor, enzyme, or transporter, SEMA3F-AS1 is actively investigated as a therapeutic target and biomarker in oncology[3][4][5].
- Other names
- SEMA3F-AS1(incorrectly listed) RBM5-AS1
02
Mechanism of action
Epigenetic regulation of target gene expression via recruitment of chromatin remodeling complexes; Histone modification (e.g., influencing H3K27 methylation or H3K9 acetylation of target gene promoter regions[3]); Antisense inhibition or upregulation of cognate gene (SEMA3F, RBM5) with downstream effects on cell cycle, proliferation, invasion, and apoptosis[3][4]
03
Biological functions
Gene expression regulationEpigenetic modulation (chromatin remodeling, histone modification)Modulation of cell proliferation, migration, and invasion (based on analogous lncRNA mechanisms[4][5])May regulate apoptosis and angiogenesis through modulation of cognate protein-coding gene expression[3][5]
04
Disease associations
Cancer (notably colorectal carcinoma, osteosarcoma)[3][4][5]Potential role in other malignancies driven by dysregulation of SEMA3F
05
Safety considerations
Potential off-target effects and regulatory complexity for therapeutic modulationUnknown long-term safety as lncRNA-based targets are still investigational
06
Biomarkers
SEMA3F-AS1 upregulation or downregulation as a biomarker in tumor tissue (e.g., CRC, Os)Downstream effects on SEMA3F or RBM5 expression levels in specific cancers[3][4]
Beyond the preview
Go deeper on Semaphorin 3F antisense RNA 1 (SEMA3F-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Semaphorin 3F antisense RNA 1 (SEMA3F-AS1).